GNRS: AI 评分 43/100 — AI 分析 (4月 2026)

Greenrose Holding Company Inc. operates in the cannabis industry, focusing on the production and sale of cannabis products. The company cultivates, processes, and packages medical cannabis and derivative products, positioning itself within the niche market of specialty and generic drug manufacturers.

Key Facts: AI Score: 43/100 Sector: Healthcare

公司概况

概要：

Greenrose Holding Company Inc. cultivates, processes, and sells medical cannabis and derivative products. Operating within the specialty and generic drug manufacturing sector, the company focuses on production and distribution. With a high profit margin, Greenrose faces challenges typical of the evolving cannabis market, including regulatory hurdles and competition.

GNRS是做什么的？

Founded in 2014 and headquartered in Amityville, New York, Greenrose Holding Company Inc. is a cannabis company involved in the production and sale of cannabis products. Through its subsidiaries, the company cultivates, processes, and packages medical cannabis and derivative products. Greenrose aims to serve the medical cannabis market by providing a range of products derived from cannabis. The company’s operations encompass the entire value chain from cultivation to packaging, ensuring quality control and product consistency. Greenrose’s strategy focuses on capturing a significant share of the market by leveraging its production capabilities and distribution network. The company operates in a highly regulated environment and must navigate complex legal frameworks at both state and federal levels. Greenrose is committed to adhering to the highest standards of compliance and safety in its operations. The company's current market position is influenced by the evolving legal landscape and increasing acceptance of medical cannabis.

GNRS的投资论点是什么？

Greenrose Holding Company Inc. presents a speculative investment opportunity within the cannabis sector. The company's high profit margin of 70.6% and gross margin of 59.1% suggest efficient operations, but the lack of market capitalization data and a negative beta of -170.34 indicate high volatility and potential risk. Growth catalysts include expanding product lines and entering new geographic markets as regulations evolve. However, investors should be aware of the risks associated with OTC-traded companies, including limited liquidity and disclosure. The company's success hinges on navigating regulatory hurdles and achieving sustainable growth in a competitive market.

GNRS在哪个行业运营？

Greenrose Holding Company Inc. operates within the rapidly expanding cannabis industry, specifically in the specialty and generic drug manufacturing segment. The industry is characterized by evolving regulations, increasing acceptance of medical cannabis, and growing market demand. Companies like Greenrose face competition from both established players and new entrants. The market is driven by increasing legalization efforts and the growing recognition of cannabis's therapeutic benefits. The industry is also subject to significant regulatory scrutiny, impacting market access and operational costs.

Drug Manufacturers - Specialty & Generic

Healthcare

GNRS有哪些增长机遇？

Expanding Product Lines: Greenrose can capitalize on the growing demand for diverse cannabis products by expanding its product lines to include edibles, concentrates, and topicals. The market for cannabis edibles alone is projected to reach $5 billion by 2028, presenting a significant revenue opportunity. Timeline: Within the next 2-3 years.
Entering New Geographic Markets: As cannabis legalization expands across the United States and globally, Greenrose has the opportunity to enter new geographic markets. Targeting states with favorable regulatory environments and high population densities can drive significant revenue growth. Timeline: Ongoing, contingent on regulatory changes.
Strategic Partnerships: Forming strategic partnerships with established healthcare providers and pharmaceutical companies can provide Greenrose with access to new distribution channels and customer bases. Collaborating on research and development can also lead to the creation of innovative cannabis-based therapies. Timeline: Within the next 1-2 years.
Focus on Research and Development: Investing in research and development to identify new therapeutic applications for cannabis can differentiate Greenrose from its competitors and create a competitive advantage. Developing proprietary formulations and delivery methods can also enhance the company's intellectual property portfolio. Timeline: Ongoing.
Acquisitions and Mergers: Pursuing strategic acquisitions and mergers can enable Greenrose to expand its market share, acquire new technologies, and diversify its product offerings. Targeting companies with complementary assets and capabilities can create synergies and drive long-term growth. Timeline: Opportunistic, based on market conditions.

Profit Margin of 70.6% indicates strong profitability in its operations.
Gross Margin of 59.1% reflects efficient cost management in production and sales.
Beta of -170.34 suggests the stock price moves inversely to the market, indicating high volatility.
The company operates in the rapidly evolving cannabis industry, presenting both opportunities and challenges.
Headquartered in Amityville, New York, indicating a focus on the East Coast cannabis market.

GNRS提供哪些产品和服务？

Cultivates medical cannabis.
Processes raw cannabis into usable forms.
Packages cannabis products for sale.
Sells cannabis products to dispensaries and other retailers.
Develops derivative cannabis products.
Operates in compliance with state and local regulations.

GNRS如何赚钱？

Cultivation and processing of cannabis.
Sales of cannabis products to dispensaries.
Development and sale of derivative products.
Revenue generation through product sales.

Medical cannabis dispensaries.
Retail outlets selling cannabis products.
Patients with medical cannabis prescriptions.
Consumers in states with legal recreational cannabis.

Proprietary cultivation techniques.
Established distribution network.
Brand recognition in specific markets.
Compliance with regulatory standards.

什么因素可能推动GNRS股价上涨？

Upcoming: Potential changes in federal cannabis regulations could create new market opportunities.
Ongoing: Expansion into new geographic markets as legalization efforts progress.
Ongoing: Development of new cannabis-based therapies through research and development.
Ongoing: Strategic partnerships with healthcare providers to expand distribution channels.
Ongoing: Increasing consumer acceptance of medical cannabis.

GNRS的主要风险是什么？

Potential: Increasing competition in the cannabis industry could erode market share.
Potential: Changes in regulatory landscape could negatively impact operations.
Potential: Fluctuations in cannabis prices could affect profitability.
Ongoing: OTC listing indicates higher risk due to limited disclosure and oversight.
Ongoing: Dependence on evolving regulatory environment creates uncertainty.

GNRS的核心优势是什么？

High profit margin of 70.6%.
Established cultivation and processing capabilities.
Focus on medical cannabis market.
Compliance with regulatory standards.

GNRS的劣势是什么？

OTC listing indicates higher risk.
Limited market capitalization data.
Negative beta suggests high volatility.
Dependence on evolving regulatory environment.

GNRS有哪些机遇？

Expansion into new geographic markets.
Development of new cannabis-based therapies.
Strategic partnerships with healthcare providers.
Acquisition of complementary businesses.

GNRS面临哪些威胁？

Increasing competition in the cannabis industry.
Changes in regulatory landscape.
Potential for federal prohibition.
Fluctuations in cannabis prices.

GNRS的竞争对手是谁？

BioLyte Clean Recovery Inc — Focuses on clean recovery products, differing from Greenrose's cannabis focus. — (BLEVF)
Episource LLC — Provides risk adjustment solutions, not directly competing in cannabis production. — (EPRSQ)
GWhemp, Inc. — Operates in the hemp industry, a related but distinct market from Greenrose's cannabis focus. — (GWHP)
Intellinetics, Inc. — Offers document management solutions, unrelated to cannabis production. — (INTP)
Malto Holdings Inc. — Unknown business focus, making direct comparison difficult. — (MLTO)

Key Metrics

MoonshotScore: 43/100

Company Profile

CEO: Nicole Conboy
Headquarters: Amityville, US
Employees: 91
Founded: 2020

AI Insight

AI analysis pending for GNRS

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does The Greenrose Holding Company Inc. do?

The Greenrose Holding Company Inc. engages in the production and sale of cannabis products, focusing on cultivating, processing, and packaging medical cannabis and derivative products. The company operates within the healthcare sector, specifically in the specialty and generic drug manufacturing industry. Greenrose aims to provide high-quality cannabis products to meet the growing demand for medical cannabis, while adhering to regulatory standards and expanding its market presence through strategic partnerships and product development.

What do analysts say about GNRS stock?

As of 2026-03-15, there is no available analyst consensus on GNRS stock due to its OTC listing and limited coverage. Key valuation metrics such as market capitalization are unavailable, and the negative beta suggests high volatility. the may be worth researching speculative nature of the investment and conduct thorough due diligence before investing. Growth considerations include potential regulatory changes and market expansion opportunities, but risks include competition and regulatory uncertainty. The company's high profit margin is a positive factor, but the lack of analyst coverage requires independent assessment.

What are the main risks for GNRS?

The main risks for Greenrose Holding Company Inc. include regulatory uncertainty, increasing competition, and potential fluctuations in cannabis prices. As an OTC-listed company, Greenrose faces higher risk due to limited financial disclosure and regulatory oversight. Changes in federal or state cannabis regulations could significantly impact the company's operations and profitability. Increasing competition from both established players and new entrants could erode market share. Additionally, fluctuations in cannabis prices could affect the company's revenue and profitability. Investors should carefully consider these risks before investing in GNRS.